The drugmaker is prioritizing vaccine development against high-priority pathogens, including HIV, tuberculosis and malaria, identified by the World Health Organization and the Coalition for Epidemic Preparedness Innovations.
Moderna said its clinical portfolio currently includes vaccines targeting COVID-19, HIV, Nipah and Zika, with plans to advance programs against the remaining pathogens by 2025.
The initiative is part of Moderna’s larger global public health strategy released March 7, which also includes a new program, mRNA Access, that offers global researchers use of the drugmaker’s mRNA technology to explore new vaccines.
To learn more, click here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
